InnovaRx Innova Health Strategies

F16.94

Hallucinogen use, unspecified with hallucinogen-induced mood disorder

Billable FY2026 2025-10-01 → 2026-09-30
This is the unspecified option. 6 more specific codes sit alongside it. Worth checking whether the documentation supports one of them.
Exclusions 3 never code together
F16.9code
Excludes1
  • hallucinogen abuse (F16.1-)F16.1-
  • hallucinogen dependence (F16.2-)F16.2-
F01-F99chapter
Excludes2
  • symptoms, signs and abnormal clinical laboratory findings, not elsewhere classified (R00-R99)R00-R99

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 8
F16.94code
Inclusion terms
  • Other hallucinogen induced bipolar or related disorder, without use disorder
  • Other hallucinogen induced depressive disorder, without use disorder
  • Phencyclidine induced bipolar or related disorder, without use disorder
  • Phencyclidine induced depressive disorder, without use disorder
F16code
Includes
  • ecstasy
  • PCP
  • phencyclidine
F01-F99chapter
Includes
  • disorders of psychological development
Index entries leading here 3
  • Phencyclidine-induced
    • bipolar and related disorder F16.94
    • depressive disorder F16.94
  • Disorder (of) — see also Disease
    • mood F39
      • due to (secondary to)
  • Use (of)
Alongside this code 6 same parent — F16.9
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC55 CMS28HCC137 ESRD21HCC55 ESRD24HCC55

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
F16.9
Block
F10-F19
Siblings
6

Present FY2024–FY2027.